References
- Adler V., Yin Z., Fuchs S. Y., Benezra M., Rosario L., Tew K. D., Pincus M. R., Sardana M., Henderson C. J., Wolf C. R., Davis R. J., Ronai Z. Regulation of JNK signaling by GSTp. EMBO J. 1999; 18: 1321–1334, [PUBMED], [INFOTRIEVE], [CSA]
- Anwar A., Siegel D., Kepa J. K., Ross D. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone reductase 1. J. Biol. Chem. 2002; 16: 14060–14067, [CROSSREF]
- Anwar A., Dehn D., Siegel D., Kepa J. K., Tang L. J., Pietenpol J. A., Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell‐free systems. J. Biol. Chem. 2003; 278: 10368–10373, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ashcroft M., Taya Y., Vousden K. H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 2000; 20: 3224–3233, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53‐dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 1188–1193, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Asher G., Lotem J., Kama R., Sachs L., Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 3099–3104, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Beall H. D., Liu Y., Siegel D., Bolton E. M., Gibson N. W., Ross D. Role of NAD(P)H:quinone oxidoreductase (DT‐diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol. 1996; 51: 645–652, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Benson A. M., Hunkler M. J., Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. U. S. A. 1980; 77: 5216–5220, [PUBMED], [INFOTRIEVE]
- Beyer R. E., Segura‐Aguilar J., Di Bernardo S., Cavazzoni M., Fato R., Fiorentini D., Galli M., Setti M., Landi L., Lenaz G. The role of DT‐diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 2528–2532, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Boothman D., Meyers M., Fukunaga N., Lee S. W. Isolation of x ray‐inducible transcripts from radioresistant human melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 7200–7204, [PUBMED], [INFOTRIEVE], [CSA]
- Bourdon J. C., Laurenzi V. D., Melino G., Lane D. p53: 25 years of research and more questions to answer. Cell Death Differ. 2003; 10: 397–399, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cadenas E., Hochstein P., Ernster L. Pro‐ and antioxidant functions of quinones and quinone reductases in mammalian cells. Adv. Enzymol. Relat. Areas Mol. Biol. 1992; 65: 97–146, [PUBMED], [INFOTRIEVE], [CSA]
- Cavelier G., Amzel L. M. Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin. Proteins 2001; 43: 420–432, [PUBMED], [INFOTRIEVE], [CSA]
- Chen H., Lum A., Seifried A., Wilkens L. R., Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609 C→T polymorphism with a decreased lung cancer risk (in process citation). Cancer Res. 1999; 59: 3045–3048, [PUBMED], [INFOTRIEVE]
- Clairmont A., Sies H., Ramachandran S., Lear J. T., Smith A. G., Bowers B., Jones P. W., Fryer A. A., Strange R. C. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999; 20: 1235–1240, [PUBMED], [INFOTRIEVE], [CROSSREF]
- De Long M. J., Prochaska H. J., Talalay P. Induction of NAD(P)H:quinone reductase in murine hepatoma cells by phenolic antioxidants, azo dyes and other chemoprotectors: a model system for he study of anticarcinogens. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 787–791, [PUBMED], [INFOTRIEVE]
- Dzielendziak A., Butler J., Hoey B. M., Lea J. S., Ward T. H. Comparison of the structural and cytotoxic activity of novel 2,5‐bis(carboethoxyamino)‐3,6‐diaziridinyl‐1,4‐benzoquinone analogues. Cancer Res. 1990; 50: 2003–2008, [PUBMED], [INFOTRIEVE]
- Ernster L. Diaphorase activities in liver cytoplasmic fractions. Fed. Proc. 1958; 17: 216
- Ernster L. DT‐diaphorase. Meth. Enzymol. 1967; 10: 309–317
- Ernster L. DT‐diaphorase: a historical review. Chemica Scripta 1987; 27A: 1–13
- Ernster L., Navazio F. Soluble diaphorase in animal tissues. Acta Chem. Scand. 1958; 12: 595–602
- Faig M., Bianchet M. A., Talalay P., Chen S., Winski S., Ross D., Mario A. L. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 3177–3182, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fleming R. A., Drees J., Loggie B. W., Russell G. B., Geisinger K. R., Morris R. T., Sachs D., McQuellon R. P. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 2002; 12: 31–37, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Foster C. E., Bianchet M. A., Talalay P., Zhao Q., Amzel L. M. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999; 38: 9881–9886, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gaedigk A., Tyndale R. F., Jurima‐Romet M., Sellers E. M., Grant D. M., Leeder J. S. NAD(P)H:quinone oxidoreductase;polymorphisms and allele frequencies in Caucasian, Chinese and Canandian Native Indian and Inuit populations. Pharmacogenetics 1998; 8: 305–313, [PUBMED], [INFOTRIEVE], [CSA]
- Gibson N. W., Hartley J. A., Butler J., Siegel D., Ross D. Relationship between DT‐diaphorase‐mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol. Pharmacol. 1992; 42: 531–536, [PUBMED], [INFOTRIEVE], [CSA]
- Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact. 2000; 129: 141–170, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–299, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hoey B. M., Butler J., Swallow A. J. Reductive activation of mitomycin C. Biochemistry 1988; 27: 2608–2614, [PUBMED], [INFOTRIEVE]
- Hu L. T., Stamberb J., Pan S. S. The NAD(P)H:quinoneoxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C. Cancer Res. 1996; 56: 5253–5259, [PUBMED], [INFOTRIEVE]
- Huggins C., Fukunishi R. Induced protection of adrenal cortex against 7,12‐ dimethylbenz(a)anthracene. Influence of ethionine. Induction of menadione reductase. Incorporation of thymidine‐H3. J. Exp. Med. 1964; 119: 923–942, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hupp T. R., Lane D. P., Ball K. L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 2000; 352(Pt. 1)1–17, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Iyanagi T., Yamazaki I. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT‐diaphorase). Biochim. Biophys. Acta 1970; 216: 282–294, [PUBMED], [INFOTRIEVE]
- Jaiswal A. K., Burnett P., Adesnik M., McBride O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 1990; 29: 1899–1906, [PUBMED], [INFOTRIEVE]
- Joseph P., Jaiswal A. K. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo(a)pyrene quinone‐DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 8413–8417, [PUBMED], [INFOTRIEVE], [CSA]
- Kelland L. R., Sharp S. Y., Rogers P. M., Myers T. G., Workman P. DT‐diaphorase expression and tumor cell sensitivity to 17‐allylamino, 17‐demethoxygeldanamycin, an inhibitor of heat shock protein 90 (in process citation). J. Natl. Cancer Inst. 1999; 91: 1940–1949, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kelsey K. T., Wiencke J. K., Christiani D. C., Zuo Z., Spitz M. R., Xu X., Lee B. K., Schwartz B. S., Traver R. D., Ross D. Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br. J. Cancer 1997; 76: 852–854, [PUBMED], [INFOTRIEVE]
- Kohar I., Baca M., Suarna C., Stocker R., Southwell‐Keely P. T. Is α‐tocopherol a reservoir for α‐tocopheryl hydroquinone. Free Radic. Biol. Med. 1995; 19: 197–207, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Krajinovic M., Sinnett H., Richer C., Labuda D., Sinnett D. Role of NQO1, MPO, and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int. J. Cancer 2002; 97: 230–236, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Landi L., Fiorentini D., Galli M. C., Segura‐Aguilar J., Beyer R. E. DT‐diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Free Radic. Biol. Med. 1997; 22: 329–335, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lane D. P., Hall P. A. MDM2—arbiter of p53's destruction. Trends Biochem. Sci. 1997; 22: 372–374, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Larson R. A., Wang Y., Banerjee M., Wiemels J., Hartford C., Beau M. M., Smith M. T. Prevalence of the inactivating 609 C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy‐related myeloid leukemia (in process citation). Blood 1999; 94: 803–807, [PUBMED], [INFOTRIEVE], [CSA]
- Lewis S. J., Cherry N. M., Niven R. M., Barber P. V., Povey A. C. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001; 34: 177–183, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Li R., Bianchet M. A., Talalay P., Amzel L. M. The three dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy. Mechanism of the two electron reduction. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 8846–8850, [PUBMED], [INFOTRIEVE], [CSA]
- Li J., Lee J. M., Johnson J. A. Microarray analysis reveals an antioxidant responsive element‐driven gene set involved in conferring protection from an oxidative stress‐induced apoptosis in IMR‐32 cells. J. Biol. Chem. 2002; 277: 388–394, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lind C., Hochstein P., Ernster L. DT‐diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. 1982; 216: 178–185, [PUBMED], [INFOTRIEVE]
- Lind C., Cadenas E., Hochstein P., Ernster L. DT‐diaphorase. Purification properties and function. Methods Enzymol. 1990; 186: 287–301, [PUBMED], [INFOTRIEVE]
- Long D. J., Waikel R. L., Wang X. J., Perlaky L., Roop D. R., Jaiswal A. K. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene‐induced mouse skin carcinogenesis. Cancer Res. 2000; 60: 5913–5915, [PUBMED], [INFOTRIEVE]
- Long D. J., Waikel R. L., Wang X. J., Roop D. R., Jaiswal A. K. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12‐dimethylbenz(a)‐anthracene‐induced carcinogenesis in mouse skin. J. Natl. Cancer Inst. 2001; 93: 1166–1170, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Longuemaux S., Delomenie C., Gallou C., Mejean A., Vincent‐Viry M., Bouvier R., Droz D., Krishnamoorthy R., Galteau M. M., Junien C., Beroud C., Dupret J. M. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic‐metabolizing enzymes (in process citation). Cancer Res. 1999; 59: 2903–2908, [PUBMED], [INFOTRIEVE]
- Martius C. Die stellung des phyllochinons (Vitamin K1) in der atmungskette. Biochem. Z. 1954; 326: 26–27, [PUBMED], [INFOTRIEVE]
- Martius C. The Enzymes, Vol 7, P. D. Boyer, H. A.M.K. Lardy. Academic Press, New York 1960; 517–532
- McMahon M., Itoh K., Yamamoto M., Chanas S. A., Henderson C. J., McLellan L. I., Wolf C. R., Cavin C., Hayes J. D. The cap ‘n’ collar basic leucine zipper transcription factor Nrf2 (NF‐ E2 p45‐related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 2001; 61: 3299–3307, [PUBMED], [INFOTRIEVE]
- Moran J. L., Siegel D., Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 8150–8155, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Munday R., Smith B. L., Munday C. M. Effect of butylated hydroxyanisole on the toxicity of 2‐hydroxy‐1,4‐ naphthoquinone to rats. Chem. Biol. Interact. 1998; 108: 155–170, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N., Ino T., Utsunomiya A., Maruta A., Jin‐nai I., Kamada N., Kubota Y., Nakamura H., Shimazaki C., Horiike S., Kodera Y., Saito H., Ueda R., Wiemels J., Ohno R. Analysis of genetic polymorphism in NQO1, GST‐M1, GST‐T1, and CYP3A4 in 469 Japanese patients with therapy‐related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 2000; 6: 4091–4095, [PUBMED], [INFOTRIEVE], [CSA]
- Paull K., Camalier R., Fitzsimmons S. A., Lewis A. D., Workman P., Grever M. Correlation of DT‐diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel. Proc. Am. Assoc. Cancer Res. 1994; 35: 369
- Phillips R. M. Bioreductive activation of a series of analogues of 5‐aziridinyl‐ 3‐hydroxymethyl‐1‐methyl‐2‐(1H‐indole‐4,7‐dione) prop‐b‐ en‐a‐ol (EO9) by human DT‐diaphorase. Biochem. Pharmacol. 1996; 52: 1711–1718, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pink J. J., Planchon S. M., Tagliarino C., Varnes M. E., Siegel D., Boothman D. A. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta‐lapachone cytotoxicity. J. Biol. Chem. 2000; 275: 5416–5424, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Preusch P. C., Smalley D. M. Vitamin K1 2,3‐epoxide and quinone reduction: mechanism and inhibition. Free Radic. Res. Commun. 1990; 8: 401–415, [PUBMED], [INFOTRIEVE]
- Radjendirane V., Joseph P., Lee Y. H., Kimura S., Klein‐Szanto A. J.P., Gonzalez F. J., Jaiswal A. K. Disruption of the DT‐diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J. Biol. Chem. 1998; 273: 7382–7389, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ramos‐Gomez M., Kwak M. K., Dolan P. M., Itoh K., Yamamoto M., Talalay P., Kensler T. W. From the cover: sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor‐deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 3410–3415, [CSA], [CROSSREF]
- Rebbeck T. R., Godwin A. K., Buetow K. H. Variability in loss of constitutional heterozygosity across loci and among individuals: association with candidate genes in ductal breast carcinoma. Mol. Carcinog. 1996; 17: 117–125, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ritter J. K. Roles of glucuronidation and UDP‐glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 2000; 129: 171–193, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ross D. Quinone reductases. Comprehensive Toxicology Volume 3. Biotransformation, F. P. Guengerich. Pergamon, New York 1997; 179–198
- Ross D., Siegel D. NQO1. Functions and pharmacogenetics. Methods Enzymol. 2004; 382B: 115–143
- Ross D., Beall H., Traver R. D., Siegel D., Phillips R. M., Gibson N. W. Bioactivation of quinones by DT‐diaphorase. Molecular, biochemical and chemical studies. Oncol. Res. 1994; 6: 493–500, [PUBMED], [INFOTRIEVE], [CSA]
- Ross D., Kepa J. K., Winski S. L., Beall H. D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 2000; 129: 77–97, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rothman N., Smith M. T., Hayes R. B., Traver R. D., Hoener B. A., Campleman S., Li G. L., Dosemeci M., Linet M., Zhang L. P., Xi L. Q., Wacholder S., Lu W., Meyer K. B., Titenko‐Holland N., Stewart J. T., Yin S. N., Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQ01 609 C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997; 57: 2839–2842, [PUBMED], [INFOTRIEVE]
- Ruscoe J. E., Rosario L. A., Wang T., Gate L., Arifoglu P., Wolf C. R., Henderson C. J., Ronai Z., Tew K. D. Pharmacologic or genetic manipulation of glutathione S‐transferase P1‐1 (GSTpi) influences cell proliferation pathways. J. Pharmacol. Exp. Ther. 2001; 298: 339–345, [PUBMED], [INFOTRIEVE], [CSA]
- Sachse C., Smith G., Wilkie M. J., Barrett J. H., Waxman R., Sullivan F., Forman D., Bishop D. T., Wolf C. R. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002; 23: 1839–1849, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schulz W. A., Krummeck A., Rosinger I., Eickelmann P., Neuhas C., Ebert T., Schmitz‐Dräger B., Sies H. Increased frequency of a null allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7: 235–239, [PUBMED], [INFOTRIEVE], [CSA]
- Siegel D., Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues(1). Free Radic. Biol. Med. 2000; 29: 246–253, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT‐diaphorase): role in diaziquone‐induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990a; 50: 7293–7300, [PUBMED], [INFOTRIEVE]
- Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of mitomycin C by DT‐diaphorase: role in mitomycin C‐induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990b; 50: 7483–7489, [PUBMED], [INFOTRIEVE]
- Siegel D., Bolton E. M., Burr J. A., Liebler D. C., Ross D. The reduction of alpha‐tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha‐tocopherol hydroquinone as a cellular antioxidant. Mol. Pharmacol. 1997; 52: 300–305, [PUBMED], [INFOTRIEVE], [CSA]
- Siegel D., Franklin W. A., Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin. Cancer Res. 1998a; 4: 3083–3088, Ref Type: Generic[CSA]
- Siegel D., Franklin W. A., Ross D. Immunohistochemical staining for NAD(P)H:quinone oxidoreductase (NQO1) in normal lung and lung tumors. Proc. Am. Assoc. Cancer Res. 1998b; 39: 804
- Siegel D., Anwar A., Winski S. L., Kepa J. K., Zolman K. L., Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 2001a; 59: 263–268, [PUBMED], [INFOTRIEVE], [CSA]
- Siegel D., Ryder J., Ross D. NAD(P)H: quinone oxidoreductase 1 expression in human bone marrow endothelial cells. Toxicol. Lett. 2001b; 125: 93–98, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Siegel D., Gustafson D., Dehn D., Boonchoong P., Han J. Y., Berliner L., Ross D. NAD(P)H: quinone oxidoreductase 1 (NQO1): role as a superoxide scavenger. Free Radic. Biol. Med. 2003; 35: S14
- Siegel D., Gustafson D. L., Dehn D. L., Han J. Y., Bonnchoong P., Berliner L. J., Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1): role as a superoxide scavenger. Mol. Pharmacol. 2004; 65: 1238–1247, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Siegelmann‐Danieli N., Buetow K. H. Significance of genetic variation at the glutathione S‐transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 2002; 62: 39–45, [CSA], [CROSSREF]
- Smith M. T., Wang Y., Kane E., Rollinson S., Wiemels J. L., Roman E., Roddam P., Cartwright R., Morgan G. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 2001; 97: 1422–1426, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Smith M. T., Wang Y., Skibola C. F., Slater D. J., Nigro L. L., Nowell P. C., Lange B. J., Felix C. A. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002; 100: 4590–4593, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Steele R. J., Thompson A. M., Hall P. A., Lane D. P. The p53 tumour suppressor gene. Br. J. Surg. 1998; 85: 1460–1467, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Steiner M., Hillenbrand M., Borkowsi M., Seiter H., Schuff‐Werner P. 609 C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 1999; 135: 67–71, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Talalay P., Benson A. M. Elevation of quinone reductase activity by anticarcinogenic antioxidants. Adv. Enzyme Regul. 1981; 20: 287–300, [CROSSREF]
- Talalay P., Prochaska H. J. Mechanisms of induction of NAD(P)H:quinone reductase. Chem. Scr. 1987; 27A: 61–66
- Tedeschi G., Chen S., Massey V. Active site studies of DT‐diaphorase employing artificial flavins. J. Biol. Chem. 1995; 270: 2512–2516, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Thomas D. J., Sadler A., Subrahmanyam V. V., Siegel D., Reasor M. J., Wierda D., Ross D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells. Mol. Pharmacol. 1990; 37: 255–262, [PUBMED], [INFOTRIEVE], [CSA]
- Thor H., Smith M. T., Hartzell P., Bellomo G., Jewell S. A., Orrenius S. The metabolism of menadione (2‐methyl‐1,4‐naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J. Biol. Chem. 1982; 257: 12419–12425, [PUBMED], [INFOTRIEVE]
- Traver R. D., Horikoshi T., Danenberg K. D., Stadlbauer T. H. W., Danenberg P. V., Ross D., Gibson N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT‐diaphorase activity and mitomycin sensitivity. Cancer Res. 1992; 52: 797–802, [PUBMED], [INFOTRIEVE]
- Traver R. D., Siegel D., Beall H. D., Phillips R. M., Gibson N. W., Franklin W. A., Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT‐diaphorase). Br. J. Cancer 1997; 75: 69–75, [PUBMED], [INFOTRIEVE]
- Van Bladeren P. J. Glutathione conjugation as a bioactivation reaction. Chem. Biol. Interact. 2000; 129: 61–76, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vousden K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 2002; 1602: 47–59, [PUBMED], [INFOTRIEVE]
- Vousden K. H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002; 2: 594–604, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wallin R., Rannels S. R., Martin L. F. DT‐diaphorase and vitamin K dependent carboxylase in liver and lung microsomes and in macrophages and type II epithelial cells isolated from rat lung. Chem. Scr. 1987; 27A: 193–202
- Wang T., Arifoglu P., Ronai Z., Tew K. D. Glutathione S‐transferase P1‐1 (GSTP1‐1) inhibits c‐Jun N‐terminal kinase (JNK1) signaling through interaction with the C terminus. J. Biol. Chem. 2001; 276: 20999–21003, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wiemels J. L., Pagnamenta A., Taylor G. M., Eden O. B., Alexander F. E., Greaves M. F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators (in process citation). Cancer Res. 1999; 59: 4095–4099, [PUBMED], [INFOTRIEVE]
- Wiencke J. T., Spitz M. R., McMillan A., Kelsey K. T. Lung cancer in Mexican‐Americans and African‐Americans is associated with the wild type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol. Biomark. Prev. 1997; 6: 87–92, [CSA]
- Winski S., Hargreaves R. H.J., Butler J., Ross D. A new screening system for NAD(P)H:quinone oxidoreductase(NQO1)‐directed antitumor quinones > Identification of a new aziridinylbenzoquinone, RH1, as a NQO1‐directed antitumor agent. Clin. Cancer Res. 1998; 4: 3083–3088, [PUBMED], [INFOTRIEVE], [CSA]
- Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003; 3: 297–300, [PUBMED], [INFOTRIEVE], [CSA]
- Wu K., Knox R., Sun X. Z., Joseph P., Jaiswal A. K., Zhang D., Deng P. S., Chen S. Catalytic properties of NAD(P)H:quinone oxidoreductase‐2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997; 347: 221–228, [PUBMED], [INFOTRIEVE], [CSA]
- Zhao Q. J., Yang X. L., Holtzclaw W. D., Talalay P. Unexpected genetic and structural relationships of a long‐forgotten flavoenzyme to NAD(P)H:quinone reductase (DT‐diaphorase). Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 1669–1674, [PUBMED], [INFOTRIEVE], [CSA]